Literature DB >> 17892761

The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome.

Giovanni Tarantino1, Roberto Lobello, Francesco Scopacasa, Franco Contaldo, Fabrizio Pasanisi, Michele Cirillo, Maurizio De Caterina, Paolo Conca, Daniela Terracciano, Nicola Gennarelli, Manuela Ariello, Claudia Mazzarella, Ernesto Grimaldi, Vincenzo Macchia.   

Abstract

PURPOSE: To examine differences in peripheral vascular endothelial growth factor (VEGF), interleukin-6 (IL6) and cortisol concentrations between patients with both visceral obesity and metabolic syndrome, and lean controls. In a subsample of metabolic patients underwent abdominal surgery, the adipokine concentrations were measured in venous blood from the omentum to determine information on some processes of synthesis.
METHODS: Forty-two healthy lean controls and 46 overweight-obese patients with central adiposity and stigmata of metabolic syndrome were studied. In a subsample of 11 metabolic patients undergoing non-bariatric surgery, blood samples from omental and peripheral veins were taken intraoperatively to determine VEGF, IL6 and cortisol concentrations.
RESULTS: Median levels (range) of peripheral VEGF and IL6 were higher in patients than in controls [31.5 (3-112) pg/mL vs 21.35 (9-41.9) pg/mL (P < 0.05) and 5.50 (1.40-13) pg/mL vs 1.15 (0.3-1) pg/mL (P < 0.0001)]. On the other hand, concentrations of VEGF and IL6 from the omental and peripheral veins were similar in the surgery sub-group. Peripheral cortisol concentrations were not higher in patients than in controls, nor were omental concentrations different from the peripheral. Omental and peripheral VEGF and cortisol values were correlated, whereas no association was found between omental and peripheral IL6.
CONCLUSIONS: In the presence of abdominal obesity, VEGF and IL6 concentrations are increased in the systemic circulation. The contribution of visceral adipose tissue to circulating levels of VEGF and IL6 was modest.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17892761     DOI: 10.25011/cim.v30i5.2895

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  8 in total

Review 1.  Vascular endothelial growth factor from embryonic status to cardiovascular pathology.

Authors:  Mohsen Azimi-Nezhad
Journal:  Rep Biochem Mol Biol       Date:  2014-04

Review 2.  Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.

Authors:  Giovanni Tarantino; Silvia Savastano; Annamaria Colao
Journal:  World J Gastroenterol       Date:  2010-10-14       Impact factor: 5.742

3.  Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  Hepatol Int       Date:  2012-10-26       Impact factor: 6.047

4.  Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.

Authors:  Roland H Stimson; Jonas Andersson; Ruth Andrew; Doris N Redhead; Fredrik Karpe; Peter C Hayes; Tommy Olsson; Brian R Walker
Journal:  Diabetes       Date:  2008-10-13       Impact factor: 9.461

5.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

Review 6.  Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 7.  Hepatic Steatosis as a Marker of Metabolic Dysfunction.

Authors:  Elisa Fabbrini; Faidon Magkos
Journal:  Nutrients       Date:  2015-06-19       Impact factor: 5.717

Review 8.  Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD?

Authors:  Giovanni Tarantino; Vincenzo Citro; Mauro Cataldi
Journal:  Viruses       Date:  2021-07-01       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.